Quarterly report pursuant to Section 13 or 15(d)

Organization, Description of Business, Basis of Presentation, Merger with NovellusDx, Ltd., Recently Adopted Accounting Standards, Acquisition, Reclassifications and Recent Accounting Pronouncements - Revenue Recognition (Details)

v3.10.0.1
Organization, Description of Business, Basis of Presentation, Merger with NovellusDx, Ltd., Recently Adopted Accounting Standards, Acquisition, Reclassifications and Recent Accounting Pronouncements - Revenue Recognition (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Jan. 01, 2018
Dec. 31, 2017
Consolidated Statements of Operations and Other Comprehensive Loss            
Revenue $ 5,940 $ 8,028 $ 20,643 $ 21,598    
CURRENT LIABILITIES            
Deferred revenue 2,409   2,409     $ 516
NON-CURRENT LIABILITIES            
Deferred revenue, long-term 442   442     429
STOCKHOLDERS’ EQUITY            
Accumulated (deficit) (153,951)   (153,951)     $ (134,834)
Biopharma Services            
Consolidated Statements of Operations and Other Comprehensive Loss            
Revenue 3,850 4,168 11,099 11,175    
CURRENT LIABILITIES            
Deferred revenue 1,180   1,180      
NON-CURRENT LIABILITIES            
Deferred revenue, long-term 428   428      
Clinical Services            
Consolidated Statements of Operations and Other Comprehensive Loss            
Revenue 1,555 2,880 6,019 8,887    
CURRENT LIABILITIES            
Deferred revenue 0   0      
NON-CURRENT LIABILITIES            
Deferred revenue, long-term 0   0      
Discovery Services            
Consolidated Statements of Operations and Other Comprehensive Loss            
Revenue 535 $ 980 3,525 $ 1,536    
CURRENT LIABILITIES            
Deferred revenue 1,229   1,229      
NON-CURRENT LIABILITIES            
Deferred revenue, long-term 14   14      
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09            
Consolidated Statements of Operations and Other Comprehensive Loss            
Revenue (35)   (1,447)      
CURRENT LIABILITIES            
Deferred revenue (1,062)   (1,062)      
NON-CURRENT LIABILITIES            
Deferred revenue, long-term 0   0      
STOCKHOLDERS’ EQUITY            
Accumulated (deficit) 1,062   1,062   $ (2,500)  
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09 | Biopharma Services            
Consolidated Statements of Operations and Other Comprehensive Loss            
Revenue (35)   (797)      
CURRENT LIABILITIES            
Deferred revenue (1,062)   (1,062)   1,900  
NON-CURRENT LIABILITIES            
Deferred revenue, long-term 0   0      
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09 | Clinical Services            
Consolidated Statements of Operations and Other Comprehensive Loss            
Revenue 0   0      
CURRENT LIABILITIES            
Deferred revenue 0   0      
NON-CURRENT LIABILITIES            
Deferred revenue, long-term 0   0      
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09 | Discovery Services            
Consolidated Statements of Operations and Other Comprehensive Loss            
Revenue 0   (650)      
CURRENT LIABILITIES            
Deferred revenue 0   0   $ 600  
NON-CURRENT LIABILITIES            
Deferred revenue, long-term 0   0      
Calculated under Revenue Guidance in Effect before Topic 606            
Consolidated Statements of Operations and Other Comprehensive Loss            
Revenue 5,905   19,196      
CURRENT LIABILITIES            
Deferred revenue 1,347   1,347      
NON-CURRENT LIABILITIES            
Deferred revenue, long-term 442   442      
STOCKHOLDERS’ EQUITY            
Accumulated (deficit) (152,889)   (152,889)      
Calculated under Revenue Guidance in Effect before Topic 606 | Biopharma Services            
Consolidated Statements of Operations and Other Comprehensive Loss            
Revenue 3,815   10,302      
CURRENT LIABILITIES            
Deferred revenue 118   118      
NON-CURRENT LIABILITIES            
Deferred revenue, long-term 428   428      
Calculated under Revenue Guidance in Effect before Topic 606 | Clinical Services            
Consolidated Statements of Operations and Other Comprehensive Loss            
Revenue 1,555   6,019      
CURRENT LIABILITIES            
Deferred revenue 0   0      
NON-CURRENT LIABILITIES            
Deferred revenue, long-term 0   0      
Calculated under Revenue Guidance in Effect before Topic 606 | Discovery Services            
Consolidated Statements of Operations and Other Comprehensive Loss            
Revenue 535   2,875      
CURRENT LIABILITIES            
Deferred revenue 1,229   1,229      
NON-CURRENT LIABILITIES            
Deferred revenue, long-term $ 14   $ 14